Study: Oral THC Safe and Effective for Treatment of Spasticity in Pediatric Patients

Photo Credit: The Daily Chronic

Photo Credit: The Daily Chronic

According to clinical data published in the European Journal of Pediatric Neurology, the oral synthetic THC Dronabinol is both safe and effective when treating refractory spasticity in pediatric patients. The study coming from the University of Dusseldorf, Germany, has found two daily doses of oral THC effectively reduced spasticity without producing serious or enduring side effects in the majority of 16 adolescents who suffered from complex neurological conditions. The treatment regimen lasted about 181 days, and the study is one of the first of its kind to look at the safety and efficacy of THC for treating adolescent patient populations. Authors said of their results, "Our data shows evidence that dronabinol can effectively be administered over a longer period of time to... young children... without severe side effects or aggravation of pre-existing concurrent conditions." 

This information has been brought to you by the Daily Chronic and approved by our Chief Medical Officer. You can also find the abstract of this study here